Vapotherm, Inc. (VAPO)
USD 2.17
(-0.46%)
USD 2.17
(-0.46%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 112.39 Million USD | 13.18% |
| 2022 | 99.3 Million USD | 114.33% |
| 2021 | 46.33 Million USD | 4.03% |
| 2020 | 44.54 Million USD | -1.63% |
| 2019 | 45.27 Million USD | 31.32% |
| 2018 | 34.48 Million USD | 57.07% |
| 2017 | 21.95 Million USD | 83.67% |
| 2016 | 11.95 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 122.64 Million USD | 5.22% |
| 2024 Q1 | 116.56 Million USD | 3.72% |
| 2023 Q4 | 112.39 Million USD | 7.63% |
| 2023 Q1 | 99.27 Million USD | -0.04% |
| 2023 Q2 | 104.52 Million USD | 5.29% |
| 2023 FY | 112.39 Million USD | 13.18% |
| 2023 Q3 | 104.42 Million USD | -0.1% |
| 2022 Q3 | 105.28 Million USD | 1.23% |
| 2022 Q1 | 98.54 Million USD | 112.69% |
| 2022 Q2 | 104 Million USD | 5.54% |
| 2022 Q4 | 99.3 Million USD | -5.68% |
| 2022 FY | 99.3 Million USD | 114.33% |
| 2021 Q3 | 41.43 Million USD | -2.71% |
| 2021 Q4 | 46.33 Million USD | 11.83% |
| 2021 Q2 | 42.58 Million USD | -4.43% |
| 2021 Q1 | 44.56 Million USD | 0.04% |
| 2021 FY | 46.33 Million USD | 4.03% |
| 2020 FY | 44.54 Million USD | -1.63% |
| 2020 Q1 | 46.34 Million USD | 2.36% |
| 2020 Q2 | 46.42 Million USD | 0.16% |
| 2020 Q4 | 44.54 Million USD | -4.2% |
| 2020 Q3 | 46.49 Million USD | 0.16% |
| 2019 Q2 | 44.8 Million USD | -1.64% |
| 2019 Q3 | 44.62 Million USD | -0.4% |
| 2019 Q4 | 45.27 Million USD | 1.46% |
| 2019 FY | 45.27 Million USD | 31.32% |
| 2019 Q1 | 45.55 Million USD | 32.12% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | 34.48 Million USD | 57.07% |
| 2018 Q4 | 34.48 Million USD | 4.91% |
| 2018 Q3 | 32.86 Million USD | 0.0% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 21.95 Million USD | 0.0% |
| 2017 FY | 21.95 Million USD | 83.67% |
| 2016 FY | 11.95 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott Laboratories | 15.87 Billion USD | 99.292% |
| Allurion Technologies Inc. | 41.85 Million USD | -168.514% |
| Artivion, Inc. | 359.34 Million USD | 68.723% |
| Avanos Medical, Inc. | 209.1 Million USD | 46.25% |
| Butterfly Network, Inc. | 25.02 Million USD | -349.083% |
| Butterfly Network, Inc. | 25.02 Million USD | -349.083% |
| Bio-Rad Laboratories, Inc. | 1.4 Billion USD | 92.006% |
| Boston Scientific Corporation | 9.49 Billion USD | 98.816% |
| Perspective Therapeutics, Inc. | - USD | -Infinity% |
| CONMED Corporation | 991.25 Million USD | 88.662% |
| Edwards Lifesciences Corporation | 694.9 Million USD | 83.826% |
| Paragon 28, Inc. | 112.03 Million USD | -0.323% |
| Glaukos Corporation | 383.73 Million USD | 70.711% |
| Globus Medical, Inc. | 520.4 Million USD | 78.403% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -352.355% |
| Integer Holdings Corporation | 1.04 Billion USD | 89.203% |
| Medtronic plc | 26.04 Billion USD | 99.569% |
| Nevro Corp. | 221.82 Million USD | 49.333% |
| Owlet, Inc. | 15.21 Million USD | -638.644% |
| Penumbra, Inc. | 234.34 Million USD | 52.04% |
| Vicarious Surgical Inc. | 14.83 Million USD | -657.767% |
| Smith & Nephew plc | 3.08 Billion USD | 96.356% |
| Sonendo, Inc. | 40.35 Million USD | -178.536% |
| STERIS plc | 3.38 Billion USD | 96.678% |
| Stryker Corporation | 12.99 Billion USD | 99.135% |
| Zimmer Biomet Holdings, Inc. | 5.99 Billion USD | 98.125% |